Loading data for VCYT — first visit, this takes a few seconds.

Alerta

Veracyte Inc. (VCYT)

NasdaqGM: VCYT · Precio en tiempo real · USD

42.45

+1.77 (4.35%)

Al cierre: Aug 18, 2026, 3:59 PM

4.35% (1D)

Precio de compra	33.3
Capitalización de mercado	3.41B
Ingresos (TTM)	561.9M
Beneficio neto (TTM)	114.48M
Beta	1.94
EPS (TTM)	1.4
Ratio PER (TTM)	30.33
Adelante PE	21.79
P/B (TTM)	2.57
P/S (TTM)	6.07
Earnings Date	Nov 3, 2026

Precio de venta	59.52
Volumen	900,407
Volumen medio (20D)	1,334,545
Abierto	41.92
Anterior Cerrar	40.68
Rango del día	40.09 - 42.52
Rango de 52 semanas	28.25 - 60.91
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nC...

[Leer más]

Industria Diagnostics & Research

Sector Healthcare

IPO Fecha Oct 30, 2013

Empleados 755

Bolsa de Valores NasdaqGM

Símbolo bursátil VCYT

Sitio web https://www.veracyte.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Veracyte fueron 517.14M, un aumento de 16.01% en comparación con 445.76M del año anterior. Las ganancias fueron 66.35M, un aumento de 174.89%.

Estados financieros

Sorpresa de resultados

Veracyte ha publicado sus resultados trimestrales en Jul 30, 2026:

Ingresos de $150.32M falla las estimaciones por $0, con 15.49% Crecimiento interanual.

EPS de 0.54 supera las estimaciones en 0.11, con 22.73% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Veracyte Inc. publique sus resultados el Nov 3, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

2 semanas hace · MarketBeat

Veracyte Q2 Earnings Call Highlights

Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD r...

2 semanas hace · Simply Wall St.

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?

Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second quarter and first half earnings results. See our ...

2 semanas hace · GuruFocus.com

Veracyte Inc (VCYT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Launches ...

Veracyte Inc (VCYT) raises full-year guidance after delivering 15% revenue growth and launching Prosigna and TrueMRD, positioning for long-term expansion.

2 semanas hace · Zacks

Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of +25.58% and +4.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 semanas hace · Insider Monkey

Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a...

Página 1 de 2

Veracyte Inc. (VCYT)